Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical ApplicationsCambridge University Press, 11/04/2013 With this fully revised fourth edition, Dr Stahl returns to the essential roots of what it means to become a neurobiologically empowered psychopharmacologist, expertly guided in the selection and combination of treatments for individual patients in practice. Embracing the unifying themes of 'symptom endophenotypes', dimensions of psychopathology that cut across syndromes, and 'symptoms and circuits', every aspect of the text has been updated to the frontiers of current knowledge, with the clarity of explanation and illustration that only Dr Stahl can bring. Integrating much of the basic neuroscience into the clinical chapters, and with major additions in the areas of psychosis, antipsychotics, antidepressants, impulsivity, compulsivity and addiction, this is the single most readily readable source of information on disease and drug mechanisms. This remains the essential text for all students and professionals in mental health seeking to understand and utilize current therapeutics, and to anticipate the future for novel medications. |
المحتوى
Transporters receptors and enzymes as targets | |
action | |
OOlO3Ul Psychosis and schizophrenia | |
Antidepressants | |
Mood stabilizers | |
Anxiety disorders and anxiolytics | |
Chronic pain and its treatment | |
Disorders of sleep and wakefulness and their treatment | |
Dementia and its treatment | |
Impulsivity compulsivity and addiction | |
Suggested reading and selected references | |
Index | |
طبعات أخرى - عرض جميع المقتطفات
عبارات ومصطلحات مألوفة
5HT1A partial 5HT2A receptors acid activity ADHD agents Alzheimer’s disease amygdala amyloid antagonism antagonist antidepressant actions anxiety disorders aripiprazole atypical antipsychotics autoreceptors axon benzodiazepines bipolar disorder block calcium channels cause cell chronic clinical clozapine conventional antipsychotics D2 receptors dementia depressive episode discussed in Chapter DLPFC dopamine dopamine pathway dopamine release doses efficacy enzyme full agonist function GABA GABAA receptors gene glutamate glycine histamine hypnotics hypothetically increased inhibition insomnia kinase levels ligand-gated ion channels major depressive mania MAO-A MAOI mechanism of action mesolimbic messenger monoamine mood stabilizers neuron neurotransmitter NMDA receptors norepinephrine normal nucleus orexin pain partial agonist patients pharmacologic positive symptoms postsynaptic potential prefrontal cortex presynaptic protein psychiatric psychopharmacology psychosis psychotropic drugs quetiapine receptors Figure reduce regulate reuptake inhibitors risk schizophrenia sedation serotonin reuptake SERT side effects signal transduction sleep SNRIs sodium spectrum SSRIs stimulation striatum subtypes subunits symptoms of schizophrenia synapse target therapeutic transporter trazodone treatment voltage-sensitive